共 172 条
[11]
Vichi F(2020)HIV drug resistance profile in South Africa: findings and implications from the 2017 national HIV household survey PLoS ONE 15 e0241071-1684
[12]
Ceccherini-Silberstein F(2012)Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa PLoS ONE 7 e32144-1432
[13]
Blanco JL(2016)Prevalence of antiretroviral drug resistance in patients who are not responding to protease inhibitor–based treatment: results from the first national survey in South Africa J Infect Dis 214 1826-341
[14]
Marcelin AG(2020)Drug resistance mutations against protease, reverse transcriptase and integrase inhibitors in people living with HIV-1 receiving boosted protease inhibitors in South Africa Front Microbiol 11 438-135
[15]
Katlama C(2013)Field evaluation of a broadly sensitive HIV-1 In-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country J Clin Microbiol 51 529-1000
[16]
Martinez E(2006)Web resources for HIV type 1 genotypic-resistance test interpretation Clin Infect Dis 42 1608-84
[17]
Naeger LK(2012)High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen AIDS 26 1679-175
[18]
Harrington P(2015)High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa PLoS ONE 10 e0118145-1644
[19]
Komatsu T(2021)Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen AIDS 35 1423-26
[20]
Deming D(2021)Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV N Engl J Med 385 330-e17518